BioArctic AB (BIOA B) NPV

BioArctic AB is a Sweden‑based biopharmaceutical company specializing in the discovery and development of disease‑modifying treatments for neurodegenerative disorders. The Company’s primary focus is on conditions that affect the central nervous system (CNS), including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS), areas characterized by high unmet medical need and limited effective therapies. BioArctic AB conducts advanced research and development of innovative biological drugs, with a particular emphasis on monoclonal antibodies designed to target the underlying disease mechanisms rather than only alleviating symptoms. The Company combines in‑house scientific expertise with strategic collaborations with global pharmaceutical partners to advance and commercialize its therapeutic candidates worldwide.